vs
Side-by-side financial comparison of AerSale Corp (ASLE) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $90.9M, roughly 1.1× AerSale Corp). AerSale Corp runs the higher net margin — 5.9% vs -29.4%, a 35.4% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -4.0%). AerSale Corp produced more free cash flow last quarter ($9.8M vs $-34.8M).
AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
ASLE vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $90.9M | $103.7M |
| Net Profit | $5.4M | $-30.5M |
| Gross Margin | 34.1% | 52.0% |
| Operating Margin | 7.8% | -31.7% |
| Net Margin | 5.9% | -29.4% |
| Revenue YoY | -4.0% | 16.9% |
| Net Profit YoY | 99.7% | 3.4% |
| EPS (diluted) | $0.10 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $90.9M | $103.7M | ||
| Q3 25 | $71.2M | — | ||
| Q2 25 | $107.4M | — | ||
| Q1 25 | $65.8M | — | ||
| Q4 24 | $94.7M | — | ||
| Q3 24 | $82.7M | — | ||
| Q2 24 | $77.1M | — | ||
| Q1 24 | $90.5M | — |
| Q4 25 | $5.4M | $-30.5M | ||
| Q3 25 | $-120.0K | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $-5.3M | — | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | — | ||
| Q2 24 | $-3.6M | — | ||
| Q1 24 | $6.3M | — |
| Q4 25 | 34.1% | 52.0% | ||
| Q3 25 | 30.2% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 27.3% | — | ||
| Q4 24 | 31.4% | — | ||
| Q3 24 | 28.6% | — | ||
| Q2 24 | 28.2% | — | ||
| Q1 24 | 31.8% | — |
| Q4 25 | 7.8% | -31.7% | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 11.7% | — | ||
| Q1 25 | -10.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | -2.4% | — | ||
| Q1 24 | 5.2% | — |
| Q4 25 | 5.9% | -29.4% | ||
| Q3 25 | -0.2% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | -8.0% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | -4.7% | — | ||
| Q1 24 | 6.9% | — |
| Q4 25 | $0.10 | $-0.50 | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.18 | — | ||
| Q1 25 | $-0.10 | — | ||
| Q4 24 | $0.05 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $197.9M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $424.4M | $456.1M |
| Total Assets | $640.5M | $638.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.4M | $197.9M | ||
| Q3 25 | $5.3M | — | ||
| Q2 25 | $5.7M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | $9.8M | — | ||
| Q2 24 | $4.3M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
| Q4 25 | $424.4M | $456.1M | ||
| Q3 25 | $417.1M | — | ||
| Q2 25 | $415.9M | — | ||
| Q1 25 | $406.5M | — | ||
| Q4 24 | $455.6M | — | ||
| Q3 24 | $451.5M | — | ||
| Q2 24 | $449.8M | — | ||
| Q1 24 | $452.0M | — |
| Q4 25 | $640.5M | $638.1M | ||
| Q3 25 | $646.3M | — | ||
| Q2 25 | $646.7M | — | ||
| Q1 25 | $646.1M | — | ||
| Q4 24 | $604.7M | — | ||
| Q3 24 | $601.5M | — | ||
| Q2 24 | $598.7M | — | ||
| Q1 24 | $571.7M | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | $-24.8M |
| Free Cash FlowOCF − Capex | $9.8M | $-34.8M |
| FCF MarginFCF / Revenue | 10.8% | -33.5% |
| Capex IntensityCapex / Revenue | 1.7% | 9.6% |
| Cash ConversionOCF / Net Profit | 2.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-29.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | $-24.8M | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $19.8M | — | ||
| Q1 25 | $-45.2M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $10.4M | — | ||
| Q2 24 | $-15.3M | — | ||
| Q1 24 | $-21.5M | — |
| Q4 25 | $9.8M | $-34.8M | ||
| Q3 25 | $-9.8M | — | ||
| Q2 25 | $18.6M | — | ||
| Q1 25 | $-47.6M | — | ||
| Q4 24 | $32.3M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $-18.9M | — | ||
| Q1 24 | $-25.0M | — |
| Q4 25 | 10.8% | -33.5% | ||
| Q3 25 | -13.8% | — | ||
| Q2 25 | 17.3% | — | ||
| Q1 25 | -72.4% | — | ||
| Q4 24 | 34.0% | — | ||
| Q3 24 | 10.7% | — | ||
| Q2 24 | -24.6% | — | ||
| Q1 24 | -27.7% | — |
| Q4 25 | 1.7% | 9.6% | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 5.6% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 3.9% | — |
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
